(This TF has a ChIP-seq peak encompassing the variant position59) Hence, we propose the diminished DNA-binding of NR5A2 to cause the reduced expression of KEAP1 in breast cancer patients carrying this somatic mutation. Here, NR5A2 is linked to breast cancer.